Overview

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
0
Participant gender:
All
Summary
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Neurobiological Technologies
Treatments:
Ancrod
Criteria
Inclusion Criteria:

- Acute, ischemic stroke with first symptoms within 6 hours of beginning treatment

- Baseline NIHSS > 5

Exclusion Criteria:

- No intracranial, extravascular blood on CT

- Hypertension (systolic > 185; diastolic > 105)

- Baseline fibrinogen level < 100 mg/dL

- Thrombocytopenia (< 100,000 / mm3)

- Recent (< 3 days) or anticipated (< 5 days) use of a thrombolytic agent

- Recent (< 14 days) or anticipated surgery